What is the share price of Orchid Pharma Ltd (ORCHPHARMA) today?
The share price of ORCHPHARMA as on 17th April 2025 is ₹775.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Orchid Pharma Ltd (ORCHPHARMA) share?
The past returns of Orchid Pharma Ltd (ORCHPHARMA) share are- Past 1 week: 7.03%
- Past 1 month: -4.67%
- Past 3 months: -52.34%
- Past 6 months: -42.42%
- Past 1 year: -27.56%
- Past 3 years: 93.05%
- Past 5 years: 4210.83%
What are the peers or stocks similar to Orchid Pharma Ltd (ORCHPHARMA)?
The peers or stocks similar to Orchid Pharma Ltd (ORCHPHARMA) include:What is the market cap of Orchid Pharma Ltd (ORCHPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Orchid Pharma Ltd (ORCHPHARMA) is ₹3926.03 Cr as of 17th April 2025.What is the 52 week high and low of Orchid Pharma Ltd (ORCHPHARMA) share?
The 52-week high of Orchid Pharma Ltd (ORCHPHARMA) is ₹1997.40 and the 52-week low is ₹684.35.What is the PE and PB ratio of Orchid Pharma Ltd (ORCHPHARMA) stock?
The P/E (price-to-earnings) ratio of Orchid Pharma Ltd (ORCHPHARMA) is 42.60. The P/B (price-to-book) ratio is 3.36.Which sector does Orchid Pharma Ltd (ORCHPHARMA) belong to?
Orchid Pharma Ltd (ORCHPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Orchid Pharma Ltd (ORCHPHARMA) shares?
You can directly buy Orchid Pharma Ltd (ORCHPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Orchid Pharma Ltd
ORCHPHARMA Share Price
775.950.01% (+0.05)
ORCHPHARMA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ORCHPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
ORCHPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 35.58 | 3.36 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.39 | 6.29 | 0.54% |
ORCHPHARMA Analyst Ratings & Forecast
Detailed Forecast 100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
ORCHPHARMA Company Profile
Orchid Pharma Limited, formerly Orchid Chemicals & Pharmaceuticals Limited, is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals.
Investor Presentation
View olderORCHPHARMA Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
43.78
1Y Return
15.50%
Buy Reco %
88.24
CIPLA
PE Ratio
29.62
1Y Return
12.46%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
66.34
1Y Return
27.80%
Buy Reco %
68.00
MANKIND
PE Ratio
55.55
1Y Return
7.76%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.34
1Y Return
2.34%
Buy Reco %
46.67
ORCHPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ORCHPHARMA Stock Summary · November 2024
In the recent earnings call, management highlighted a robust financial performance for Q2 FY '25, with sales reaching INR 222.7 crores and a 22% increase in cumulative sales for the first half of the fiscal year. Strategic collaborations, particularly with Cipla, are set to enhance market penetration for new products, while operational challenges, including delays in the Production Linked Incentive scheme, underscore the need for careful alignment of production with market demand. Despite a cautious outlook due to pricing pressures and regulatory hurdles, optimism remains around the potential of new drug launches like ORBLICEF and Enmetazobactam, which are expected to significantly impact future growth. The company’s commitment to R&D and operational excellence positions it well to navigate the complexities of the pharmaceutical landscape.
Key Points on Orchpharma Stock
ORCHPHARMA Stock Growth Drivers
7Strong Financial Performance
Orchid Pharma reported impressive financial results for Q2 FY '25, with sales reaching INR 222.7
Successful Product Launches
The company successfully launched ORBLICEF, a drug product for Enmetazobactam-Cefepime, in the Indian market, which
ORCHPHARMA Stock Challenges
3Revenue Decline and Flat Performance
The company has experienced a sequential revenue decline of approximately 8.9%, which raises concerns about
Production and Market Demand Alignment Challenges
There is a significant emphasis on the need for the company to align its production
ORCHPHARMA Forecasts
Price
Revenue
Earnings
ORCHPHARMA Share Price Forecast
2024
Current
₹775.95
Baseline
Forecast for Apr 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹775.95
Baseline
Forecast for Apr 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ORCHPHARMA Company Revenue Forecast
2024
Current
₹850.23
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2024
Current
₹850.23
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
ORCHPHARMA Stock EPS (Earnings Per Share) Forecast
2024
Current
₹20.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹20.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ORCHPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
ORCHPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 898.35 | 823.83 | 703.29 | 817.84 | 508.08 | 465.27 | 627.03 | 724.54 | 850.23 | 938.49 | ||||||||||
Raw Materials | 407.53 | 373.85 | 342.63 | 263.14 | 221.68 | 245.60 | 340.62 | 406.10 | 528.35 | 783.43 | ||||||||||
| Power & Fuel Cost | 55.28 | 54.33 | 50.69 | 48.76 | 47.44 | 39.31 | 52.74 | 61.26 | 62.92 | |||||||||||
| Employee Cost | 86.81 | 79.41 | 86.22 | 82.28 | 74.86 | 67.11 | 63.28 | 65.35 | 69.64 | |||||||||||
| Selling & Administrative Expenses | 90.77 | 104.80 | 81.40 | 55.19 | 63.82 | 36.63 | 41.92 | 34.96 | 53.17 | |||||||||||
| Operating & Other expenses | 114.80 | 267.39 | 97.74 | 162.43 | 107.19 | 32.04 | 6.42 | 20.71 | -5.77 | |||||||||||
EBITDA | 143.16 | -55.95 | 44.61 | 206.04 | -6.91 | 44.58 | 122.05 | 136.16 | 141.92 | 155.06 | ||||||||||
| Depreciation/Amortization | 145.27 | 141.05 | 133.31 | 129.94 | 117.93 | 108.92 | 87.02 | 54.79 | 33.24 | 34.10 | ||||||||||
| PBIT | -2.11 | -197.00 | -88.70 | 76.10 | -124.84 | -64.34 | 35.03 | 81.37 | 108.68 | 120.96 | ||||||||||
| Interest & Other Items | 294.24 | 346.77 | 310.26 | 6.69 | 6.23 | 52.21 | 33.46 | 32.90 | 16.74 | 14.10 | ||||||||||
| PBT | -296.35 | -543.77 | -398.96 | 69.41 | -131.07 | -116.55 | 1.57 | 48.47 | 91.94 | 106.86 | ||||||||||
| Taxes & Other Items | -17.25 | -48.34 | -46.19 | 0.00 | 0.00 | 0.00 | 3.52 | 2.15 | -0.22 | -3.47 | ||||||||||
| Net Income | -279.10 | -495.43 | -352.77 | 69.41 | -131.07 | -116.55 | -1.95 | 46.32 | 92.16 | 110.33 | ||||||||||
| EPS | -32.04 | -55.69 | -39.65 | 7.80 | -20.20 | -28.55 | -0.48 | 11.35 | 20.14 | 21.75 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ORCHPHARMA Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
Nov 11PDF
ORCHPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Orchid Pharma Ltd | 42.60 | 3.36 | — |
| Sun Pharmaceutical Industries Ltd | 43.78 | 6.25 | 0.77% |
| Cipla Ltd | 29.62 | 4.55 | 0.86% |
| Torrent Pharmaceuticals Ltd | 66.34 | 16.03 | 0.86% |
ORCHPHARMA Stock Price Comparison
Compare ORCHPHARMA with any stock or ETFCompare ORCHPHARMA with any stock or ETF
ORCHPHARMA
ORCHPHARMA Shareholdings
ORCHPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ORCHPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ORCHPHARMA Shareholding Pattern
ORCHPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in ORCHPHARMA
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Orchid Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 6.8515% | Percentage of the fund’s portfolio invested in the stock 1.08% | Change in the portfolio weight of the stock over the last 3 months -1.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/106 (-24) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.3476% | Percentage of the fund’s portfolio invested in the stock 0.53% | Change in the portfolio weight of the stock over the last 3 months -0.80% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 65/76 (-17) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3472% | Percentage of the fund’s portfolio invested in the stock 0.69% | Change in the portfolio weight of the stock over the last 3 months 0.69% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 74/101 (+22) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ORCHPHARMA stock
Looks like this stock is not in any smallcase yet.
ORCHPHARMA Events
ORCHPHARMA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ORCHPHARMA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ORCHPHARMA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeORCHPHARMA Stock News & Opinions
Articles & Videos
Corporate
Orchid Pharma continues to be under rating watch with developing implications
Orchid Pharma announced that CARE has continued the rating CARE A-/ CARE A2 while maintaining a rating watch with developing implications for bank facilities availed by the company. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Orchid Pharma's Alathur facility completes USFDA inspection
Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing. The Alathur facility specializes in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the U.S. and global markets. Additionally, the Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice (GMP) certificate following a successful inspection. This further validates the facility's compliance with European regulatory requirements and its capability to serve global markets. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Orchid Pharma consolidated net profit declines 29.39% in the December 2024 quarter
Net profit of Orchid Pharma declined 29.39% to Rs 20.78 crore in the quarter ended December 2024 as against Rs 29.43 crore during the previous quarter ended December 2023. Sales declined 1.47% to Rs 217.34 crore in the quarter ended December 2024 as against Rs 220.59 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales217.34220.59 -1 OPM %12.1316.04 - PBDT31.0639.46 -21 PBT22.4530.19 -26 NP20.7829.43 -29 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Orchid Pharma to announce Quarterly Result
Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Orchid Pharma consolidated net profit rises 37.58% in the September 2024 quarter
Net profit of Orchid Pharma rose 37.58% to Rs 27.24 crore in the quarter ended September 2024 as against Rs 19.80 crore during the previous quarter ended September 2023. Sales rose 12.04% to Rs 222.70 crore in the quarter ended September 2024 as against Rs 198.76 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales222.70198.76 12 OPM %13.6211.73 - PBDT34.5327.86 24 PBT25.9020.02 29 NP27.2419.80 38 Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Orchid Pharma consolidated net profit rises 212.23% in the June 2024 quarter
Net profit of Orchid Pharma rose 212.23% to Rs 29.35 crore in the quarter ended June 2024 as against Rs 9.40 crore during the previous quarter ended June 2023. Sales rose 33.62% to Rs 244.41 crore in the quarter ended June 2024 as against Rs 182.92 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales244.41182.92 34 OPM %13.2912.10 - PBDT36.5618.48 98 PBT28.1210.78 161 NP29.359.40 212 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Orchid Pharma announces board meeting date
Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Orchid Pharma to conduct AGM
Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held on 12 August 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Road Ahead For Orchid Pharma & Cipla's Partnership To Combat UTI I MD Manish Dhanuka Shares Outlook
9 months agoNDTV Profit
Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India
9 months agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 0.78%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 0.37% to 0.22%
Over the last 5 years, net income has grown at a yearly rate of 5.83%, vs industry avg of 15.28%